Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.35 |
| ▸ | MMP1 | P03956 | 8/20 | 0.35 |
| ▸ | MMP9 | P14780 | 8/20 | 0.35 |
| ▸ | MMP13 | P45452 | 7/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988412 | 0.82 | MMP1 (0.35) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL13034571 | 0.79 | CHRNB2 (0.45) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL15343543 | 0.74 | MMP1 (0.35) | MMP1MMP9MMP2MMP12CHRNB2 | |
| SCHEMBL4676804 | 0.73 | MMP1 (0.39) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL9357927 | 0.73 | ALDH1A1 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL19105198 | 0.73 | MMP1 (0.39) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL4677086 | 0.71 | MMP1 (0.38) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL4677082 | 0.71 | MMP1 (0.38) | ADAM17MMP1MMP9MMP13MMP2 | |
| SCHEMBL12987849 | 0.71 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL18924869 | 0.71 | TSHR (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ADAM17 3930/4885MMP1 4332/4885MMP9 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.